Ritonavir: Difference between revisions
No edit summary |
No edit summary |
||
Line 7: | Line 7: | ||
==Adult Dosing== | ==Adult Dosing== | ||
*HIV Treatment | *HIV Treatment | ||
**Protease inhibitor boosting | |||
***100-400 mg/day QD-BID | |||
**Sole protease inhibitor | |||
***600 mg PO BID | |||
***Start with 300 mg PO BID, increased by 200 mg/day every 2-3 days | |||
*HIV post-exposure prophylaxis | *HIV post-exposure prophylaxis | ||
* | **100 mg PO QID | ||
**Part of multi-drug regimen | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*HIV Treatment | *HIV Treatment | ||
**Can be given in >1 month old, dosing varies based on other concominant treatments | |||
*HIV post-exposure prophylaxis | *HIV post-exposure prophylaxis | ||
* | **Can be given in >3 years old, dosing varies based on other concominant treatments | ||
==Special Populations== | ==Special Populations== | ||
Line 81: | Line 89: | ||
==Comments== | ==Comments== | ||
A trial of [[lopinavir]]/[[ritonavir]] is currently being done to study use in [[COVID-19]]. So far, studies have not shown significant benefit in time to clinical improvement. Mortality at 28 days is lower but not statistically significant. | |||
==See Also== | ==See Also== |
Revision as of 16:49, 22 March 2020
Administration
- Type: Antiviral
- Dosage Forms: 100 mg
- Routes of Administration: PO
- Common Trade Names: Norvir
Adult Dosing
- HIV Treatment
- Protease inhibitor boosting
- 100-400 mg/day QD-BID
- Sole protease inhibitor
- 600 mg PO BID
- Start with 300 mg PO BID, increased by 200 mg/day every 2-3 days
- Protease inhibitor boosting
- HIV post-exposure prophylaxis
- 100 mg PO QID
- Part of multi-drug regimen
Pediatric Dosing
- HIV Treatment
- Can be given in >1 month old, dosing varies based on other concominant treatments
- HIV post-exposure prophylaxis
- Can be given in >3 years old, dosing varies based on other concominant treatments
Special Populations
Pregnancy Rating
- HIV: Benefits outweight risk during pregnancy. Avoid oral solution due to alcohol content.
Lactation risk
- Avoid breastfeeding
Renal Dosing
- Adult: No adjustment
- Pediatric: Not defined, but likely no adjustment as in adults
Hepatic Dosing
- Adult:
- Mild-moderate impairment: no adjustment
- Severe impairment: not defined
- Pediatric:
- Mild-moderate impairment: no adjustment
- Severe impairment: not defined
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Hepatotoxicity
- Pancreatitis
- GI bleed
- Hypersensitivity reaction
- Anaphylaxis
- Toxic epidermal necrolysis
- Stevens-Johnson syndrome
- PR prolongation/AV block
- Hypercholesterolemia/hypertriglyceridemia
- Diabetes mellitus/hyperglycemia
- Immune reconstitution syndrome
- Autoimmune disorders
- Hypertension
- Syncope
- Orthostatic hypotension
- Myopathy
- Thrombocytopenia
Common
- Nausea/vomiting
- Diarrhea
- Paresthesia
- Fatigue
- Rash
- Abdominal pain
- Cough
- Dysgeusia
- Oropharyngeal pain
- Dizziness
- AST, ALT, CK elevation
- Edema
- Acne
- Lipodystrophy
Pharmacology
- Half-life: 3-5 hours
- Metabolism: Liver (CYP450)
- Excretion: Fecal
Mechanism of Action
- Binds to active site of HIV protease, preventing maturation of the virus
Comments
A trial of lopinavir/ritonavir is currently being done to study use in COVID-19. So far, studies have not shown significant benefit in time to clinical improvement. Mortality at 28 days is lower but not statistically significant.